Applying the NCODA PQI: Encorafenib + Cetuximab + mFOLFOX6 for BRAF V600E–Mutated mCRC
When: Thursday, November 6 | 2 p.m. EST
Presenters: Jennah Bauernfeind, PharmD, BCOP | Mayo Clinic Arizona
Managing BRAF V600E-mutated metastatic colorectal cancer can be complex — especially when balancing targeted therapy with traditional chemotherapy. The combination of encorafenib, cetuximab, and mFOLFOX6 offers a promising path forward, but it brings new practical challenges for clinicians.
Jennah Bauernfeind, PharmD, BCOP, will walk through how to apply the NCODA PQI for Encorafenib, Cetuximab, and mFOLFOX6 in real-world settings.
Key Learnings:
- How to use the PQI to guide treatment decisions
- Dose verification and premedication best practices
- Managing neuropathy, rash, and cardiac risk in patients
For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.
Login to Watch this Webinar
To watch the live webinar, login to your account or register to gain access to our exclusive content.
Additional Upcoming Webinars
Upcoming Webinar
Pharmacy Perspectives: Bringing Bispecifics and 505(b)(2) Medications Into Practice
October 28, 2025 | 5:00 PM
November 3, 2025 | 2:00 PM